TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
Results from the PROfound phase III study, funded by AstraZeneca and Merck Sharp & Dohme, open up a much-needed new treatment avenue for the more precise and effective treatment of patients with ...
Arun Menawat, CEO of Profound Medical, talks about the company’s innovative TULSA-PRO technology. In a recent interview, Arun Menawat, CEO of Profound Medical, discussed the company’s innovative TULSA ...
Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...